Johnson & Johnson, Gilead HIV Drug Wins U.S. FDA Approval

Johnson & Johnson and Gilead Sciences Inc. won U.S. approval of a once-daily HIV treatment that combines multiple medicines into one tablet.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.